LYTIR

Insider · SEC Form 4 · Director, 10% Owner

CHOO CHEE KONG

Filed with the SEC as Choo Chee Kong; the order above is the one the filer's own signature uses.

In the 12 months to Nov 19, 2026, on the open market: bought $429K of GDTC. Filed a median of 8 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $429K in total; Insider sales: $0 in total.May: Insider purchases $129KJul: Insider purchases $300KDecJanFebMarAprMayJunJulAugSepOctNov$300K
Insider purchases above the line: $429KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. GDTCBought: CytoMed Therapeutics Ltd Jul 20, 2026 100,000 shares filed Jul 24, 2026 630,324 shares held directly after, as filed filing $150K
  2. GDTCBought: CytoMed Therapeutics Ltd Jul 14, 2026 100,000 shares filed Jul 24, 2026 530,324 shares held directly after, as filed filing $150K
  3. GDTCBought: CytoMed Therapeutics Ltd May 13, 2026 112,000 shares filed Jun 15, 2026 430,324 shares held directly after, as filed filing $129K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. GDTCChoo Chee Kong filed Oct 16, 2026 Schedule 13D/A may seek influence 3,003,996 shares issuer: CytoMed Therapeutics Ltd filing 25.17%
  2. GDTCChoo Chee Kong filed Oct 13, 2026 Schedule 13D/A may seek influence 2,974,746 shares issuer: CytoMed Therapeutics Ltd filing 24.92%
  3. GDTCChoo Chee Kong filed Jul 24, 2026 Schedule 13D/A may seek influence 2,899,746 shares issuer: CytoMed Therapeutics Ltd filing 24.3%